Human Antibody Therapeutics for Viral Disease pp 1-38

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 317)

Therapeutic Control of Hepatitis C Virus: The Role of Neutralizing Monoclonal Antibodies

  • K. Machida
  • Z. Y. Keck
  • M. M. C. Lai
  • J. K. Ball
  • A. H. Patel
  • S. K. H. Foung

Liver failure associated with hepatitis C virus (HCV) accounts for a substantial portion of liver transplantation. Although current therapy helps some patients with chronic HCV infection, adverse side effects and a high relapse rate are major problems. These problems are compounded in liver transplant recipients as reinfection occurs shortly after transplantation. One approach to control reinfection is the combined use of specific antivirals together with HCV-specific antibodies. Indeed, a number of human and mouse monoclonal antibodies to conformational and linear epitopes on HCV envelope proteins are potential candidates, since they have high virus neutralization potency and are directed to epitopes conserved across diverse HCV genotypes. However, a greater understanding of the factors contributing to virus escape and the role of lipoproteins in masking virion surface domains involved in virus entry will be required to help define those protective determinants most likely to give broad protection. An approach to immune escape is potentially caused by viral infection of immune cells leading to the induction hypermutation of the immunoglobulin gene in B cells. These effects may contribute to HCV persistence and B cell lymphoproliferative diseases.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allander T, Drakenberg K, Beyene A, Rosa D, Abrignani S, Houghton M, Widell A, Grillner L, Persson MA (2000) Recombinant human monoclonal antibodies against different conformational epitopes of the E2 envelope glycoprotein of hepatitis C virus that inhibit its interaction with CD81. J Gen Virol 81:2451–2459PubMedGoogle Scholar
  2. Alter HJ, Seeff LB (2000) Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 20:17–35PubMedCrossRefGoogle Scholar
  3. Altomonte M, Montagner R, Pucillo C, Maio M (1996) Triggering of target of an antiproliferative antibody-1 (TAPA-1/CD81) up-regulates the release of tumour necrosis factor-alpha by the EBV-B lymphoblastoid cell line JY. Scand J Immunol 43:367–373PubMedCrossRefGoogle Scholar
  4. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, Ogg GS, King A, Lechner F, Spina CA, Little S, Havlir DV, Richman DD, Gruener N, Pape G, Waters A, Easterbrook P, Salio M, Cerundolo V, McMichael AJ, Rowland-Jones SL (2002) Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8:379–385PubMedCrossRefGoogle Scholar
  5. Auffermann-Gretzinger S, Keeffe EB, Levy S (2001) Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection. Blood 97:3171–3176PubMedCrossRefGoogle Scholar
  6. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF (2003) Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278:41003–41012PubMedCrossRefGoogle Scholar
  7. Barth H, Ulsenheimer A, Pape GR, Diepolder HM, Hoffmann M, Neumann-Haefelin C, Thimme R, Henneke P, Klein R, Paranhos-Baccala G, Depla E, Liang TJ, Blum HE, Baumert TF (2005) Uptake and presentation of hepatitis C virus-like particles by human dendritic cells. Blood 105:3605–3614PubMedCrossRefGoogle Scholar
  8. Barth H, Schnober EK, Zhang F, Linhardt RJ, Depla E, Boson B, Cosset FL, Patel AH, Blum HE, Baumert TF (2006) Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol 80:10579–10590PubMedCrossRefGoogle Scholar
  9. Bartosch B, Bukh J, Meunier JC, Granier C, Engle RE, Blackwelder WC, Emerson SU, Cosset FL, Purcell RH (2003a) In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc Natl Acad Sci U S A 100:14199–14204PubMedCrossRefGoogle Scholar
  10. Bartosch B, Dubuisson J, Cosset FL (2003b) Infectious hepatitis C virus pseudo-particles containing functional E1–E2 envelope protein complexes. J Exp Med 197:633–642PubMedCrossRefGoogle Scholar
  11. Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL (2003c) Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J Biol Chem 278:41624–41630PubMedCrossRefGoogle Scholar
  12. Bartosch B, Verney G, Dreux M, Donot P, Morice Y, Penin F, Pawlotsky JM, Lavillette D, Cosset FL (2005) An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J Virol 79:8217–8229PubMedCrossRefGoogle Scholar
  13. Baumert TF, Ito S, Wong DT, Liang TJ (1998) Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J Virol 72:3827–3836PubMedGoogle Scholar
  14. Beaumont T, Quakkelaar E, van Nuenen A, Pantophlet R, Schuitemaker H (2004) Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker. J Virol 78:5651–5657PubMedCrossRefGoogle Scholar
  15. Bertolino P, McCaughan GW, Bowen DG (2002) Role of primary intrahepatic T-cell activation in the ‘liver tolerance effect’. Immunol Cell Biol 80:84–92PubMedCrossRefGoogle Scholar
  16. Beyene A, Basu A, Meyer K, Ray R (2002) Hepatitis C virus envelope glycoproteins and potential for vaccine development. Vox Sang 83 [Suppl 1]:27–32PubMedGoogle Scholar
  17. Biggins SW, Terrault NA (2005) Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis 9:505–523, ixPubMedCrossRefGoogle Scholar
  18. Booth JC, Kumar U, Webster D, Monjardino J, Thomas HC (1998) Comparison of the rate of sequence variation in the hypervariable region of E2/NS1 region of hepatitis C virus in normal and hypogammaglobulinemic patients. Hepatology 27:223–227PubMedCrossRefGoogle Scholar
  19. Bowen DG, Walker CM (2005a) Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436:946–952PubMedCrossRefGoogle Scholar
  20. Bowen DG, Walker CM (2005b) Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 201:1709–1714PubMedCrossRefGoogle Scholar
  21. Bowen DG, Walker CM (2005c) The origin of quasispecies: cause or consequence of chronic hepatitis C viral infection? J Hepatol 42:408–417PubMedCrossRefGoogle Scholar
  22. Brown RJ, Juttla VS, Tarr AW, Finnis R, Irving WL, Hemsley S, Flower DR, Borrow P, Ball JK (2005) Evolutionary dynamics of hepatitis C virus envelope genes during chronic infection. J Gen Virol 86:1931–1942PubMedCrossRefGoogle Scholar
  23. Brown RJ, Tarr AW, McClure CP, Juttla VS, Tagiuri N, Irving WL, Ball JK (2007) Cross-genotype characterization of genetic diversity and molecular adaptation in hepatitis C virus envelope glycoprotein genes. J Gen Virol 88:458–469PubMedCrossRefGoogle Scholar
  24. Bugli F, Mancini N, Kang CY, Di Campli C, Grieco A, Manzin A, Gabrielli A, Gasbarrini A, Fadda G, Varaldo PE, Clementi M, Burioni R (2001) Mapping B-cell epitopes of hepatitis C virus E2 glycoprotein using human monoclonal antibodies from phage display libraries. J Virol 75:9986–9990PubMedCrossRefGoogle Scholar
  25. Bukh J, Miller RH, Purcell RH (1995) Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin Liver Dis 15:41–63PubMedCrossRefGoogle Scholar
  26. Burioni R, Plaisant P, Manzin A, Rosa D, Delli Carri V, Bugli F, Solforosi L, Abrignani S, Varaldo PE, Fadda G, Clementi M (1998) Dissection of human humoral immune response against hepatitis C virus E2 glycoprotein by repertoire cloning and generation of recombinant Fab fragments. Hepatology 28:810–814PubMedCrossRefGoogle Scholar
  27. Burioni R, Bugli F, Mancini N, Rosa D, Di Campli C, Moroncini G, Manzin A, Abrignani S, Varaldo PE, Clementi M, Fadda G (2001) Nonneutralizing human antibody fragments against hepatitis C virus E2 glycoprotein modulate neutralization of binding activity of human recombinant Fabs. Virology 288:29–35PubMedCrossRefGoogle Scholar
  28. Burioni R, Mancini N, Carletti S, Perotti M, Grieco A, Canducci F, Varaldo PE, Clementi M (2004) Cross-reactive pseudovirus-neutralizing anti-envelope antibodies coexist with antibodies devoid of such activity in persistent hepatitis C virus infection. Virology 327:242–248PubMedCrossRefGoogle Scholar
  29. Burton DR, Barbas CF 3rd (1994) Human antibodies from combinatorial libraries. Adv Immunol 57:191–280PubMedCrossRefGoogle Scholar
  30. Burton DR, Saphire EO, Parren PW (2001) A model for neutralization of viruses based on antibody coating of the virion surface. Curr Top Microbiol Immunol 260:109–143PubMedGoogle Scholar
  31. Cai Z, Zhang C, Chang KS, Jiang J, Ahn BC, Wakita T, Liang TJ, Luo G (2005) Robust production of infectious hepatitis C virus (HCV) from stably HCV cDNA-transfected human hepatoma cells. J Virol 79:13963–13973PubMedCrossRefGoogle Scholar
  32. Carter RH, Fearon DT (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256:105–107PubMedCrossRefGoogle Scholar
  33. Casato M, Mecucci C, Agnello V, Fiorilli M, Knight GB, Matteucci C, Gao L, Kay J (2002) Regression of lymphoproliferative disorder after treatment for hepatitis C virus infection in a patient with partial trisomy 3, Bcl-2 overexpression, and type II cryoglobulinemia. Blood 99:2259–2261PubMedCrossRefGoogle Scholar
  34. Cerino A, Meola A, Segagni L, Furione M, Marciano S, Triyatni M, Liang TJ, Nicosia A, Mondelli MU (2001) Monoclonal antibodies with broad specificity for hepatitis C virus hypervariable region 1 variants can recognize viral particles. J Immunol 167:3878–3886PubMedGoogle Scholar
  35. Chang KM, Rehermann B, McHutchison JG, Pasquinelli C, Southwood S, Sette A, Chisari FV (1997) Immunological significance of cytotoxic T lymphocyte epitope variants in patients chronically infected by the hepatitis C virus. J Clin Invest 100:2376–2385PubMedCrossRefGoogle Scholar
  36. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, Detre K, Hoofnagle J (1998) Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 28:823–830PubMedCrossRefGoogle Scholar
  37. Chaudhuri J, Tian M, Khuong C, Chua K, Pinaud E, Alt FW (2003) Transcription-targeted DNA deamination by the AID antibody diversification enzyme. Nature 422:726–730PubMedCrossRefGoogle Scholar
  38. Choisy M, Woelk CH, Guegan JF, Robertson DL (2004) Comparative study of adaptive molecular evolution in different human immunodeficiency virus groups and subtypes. J Virol 78:1962–1970PubMedCrossRefGoogle Scholar
  39. Choo QL, Kuo G, Ralston R, Weiner A, Chien D, Van Nest G, Han J, Berger K, Thudium K, Kuo C, et al (1994) Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A 91:1294–1298PubMedCrossRefGoogle Scholar
  40. Clayton RF, Owsianka A, Aitken J, Graham S, Bhella D, Patel AH (2002) Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J Virol 76:7672–7682PubMedCrossRefGoogle Scholar
  41. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, Houghton M, Parham P, Walker CM (1999) Analysis of a successful immune response against hepatitis C virus. Immunity 10:439–449PubMedCrossRefGoogle Scholar
  42. Cooreman MP, Schoondermark-Van de Ven EM (1996) Hepatitis C virus: biological and clinical consequences of genetic heterogeneity. Scand J Gastroenterol Suppl 31:106–115CrossRefGoogle Scholar
  43. Cox AL, Mosbruger T, Mao Q, Liu Z, Wang XH, Yang HC, Sidney J, Sette A, Pardoll D, Thomas DL, Ray SC (2005) Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201:1741–1752PubMedCrossRefGoogle Scholar
  44. Crotta S, Stilla A, Wack A, D'Andrea A, Nuti S, D'Oro U, Mosca M, Filliponi F, Brunetto RM, Bonino F, Abrignani S, Valiante NM (2002) Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J Exp Med 195:35–41PubMedCrossRefGoogle Scholar
  45. Curran R, Jameson CL, Craggs JK, Grabowska AM, Thomson BJ, Robins A, Irving WL, Ball JK (2002) Evolutionary trends of the first hypervariable region of the hepatitis C virus E2 protein in individuals with differing liver disease severity. J Gen Virol 83:11–23PubMedGoogle Scholar
  46. Davis GL, Nelson DR, Terrault N, et al (2005) A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl 11:941–949PubMedCrossRefGoogle Scholar
  47. De Francesco R, Migliaccio G (2005) Challenges and successes in developing new therapies for hepatitis C. Nature 436:953–960PubMedCrossRefGoogle Scholar
  48. De Re V, De Vita S, Marzotto A, Rupolo M, Gloghini A, Pivetta B, Gasparotto D, Carbone A, Boiocchi M (2000) Sequence analysis of the immunoglobulin antigen receptor of hepatitis C virus-associated non-Hodgkin lymphomas suggests that the malignant cells are derived from the rheumatoid factor-producing cells that occur mainly in type II cryoglobulinemia. Blood 96:3578–3584PubMedGoogle Scholar
  49. De Vita S, De Re V, Gasparotto D, Ballare M, Pivetta B, Ferraccioli G, Pileri S, Boiocchi M, Monteverde A (2000) Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum 43:94–102PubMedCrossRefGoogle Scholar
  50. Depraetere S, Leroux-Roels G (1999) Hepatitis C virus envelope proteins: immunogenicity in humans and their role in diagnosis and vaccine development. Viral Hep Rev 5:113–146Google Scholar
  51. Di Noia J, Neuberger MS (2002) Altering the pathway of immunoglobulin hypermutation by inhibiting uracil-DNA glycosylase. Nature 419:43–48PubMedCrossRefGoogle Scholar
  52. Dreux M, Pietschmann T, Granier C, Voisset C, Ricard-Blum S, Mangeot PE, Keck Z, Foung S, Vu-Dac N, Dubuisson J, Bartenschlager R, Lavillette D, Cosset FL (2006) High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI. J Biol Chem 281:18285–18295PubMedCrossRefGoogle Scholar
  53. Drummer HE, Wilson KA, Poumbourios P (2002) Identification of the hepatitis C virus E2 glycoprotein binding site on the large extracellular loop of CD81. J Virol 76:11143–11147PubMedCrossRefGoogle Scholar
  54. Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, McKinney D, Sette A, Hughes AL, Walker CM (2001) The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15:883–895PubMedCrossRefGoogle Scholar
  55. Everhart JE, Wei Y, Eng H, Charlton MR, Persing DH, Wiesner RH, Germer JJ, Lake JR, Zetterman RK, Hoofnagle JH (1999) Recurrent and new hepatitis C virus infection after liver transplantation. Hepatology 29:1220–1226PubMedCrossRefGoogle Scholar
  56. Faili A, Aoufouchi S, Flatter E, Gueranger Q, Reynaud CA, Weill JC (2002) Induction of somatic hypermutation in immunoglobulin genes is dependent on DNA polymerase iota. Nature 419:944–947PubMedCrossRefGoogle Scholar
  57. Farci P, Alter HJ, Govindarajan S, Wong DC, Engle R, Lesniewski RR, Mushahwar IK, Desai SM, Miller RH, Ogata N, et al (1992) Lack of protective immunity against reinfection with hepatitis C virus. Science 258:135–140PubMedCrossRefGoogle Scholar
  58. Farci P, Alter HJ, Wong DC, Miller RH, Govindarajan S, Engle R, Shapiro M, Purcell RH (1994) Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization. Proc Natl Acad Sci U S A 91:7792–7796PubMedCrossRefGoogle Scholar
  59. Farci P, Shimoda A, Wong D, Cabezon T, De Gioannis D, Strazzera A, Shimizu Y, Shapiro M, Alter HJ, Purcell RH (1996) Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A 93:15394–15399PubMedCrossRefGoogle Scholar
  60. Farci P, Shimoda A, Coiana A, Diaz G, Peddis G, Melpolder JC, Strazzera A, Chien DY, Munoz SJ, Balestrieri A, Purcell RH, Alter HJ (2000) The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288:339–344PubMedCrossRefGoogle Scholar
  61. Fearon DT, Carter RH (1995) The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol 13:127–149PubMedCrossRefGoogle Scholar
  62. Fitch WM, Margoliash E (1967) Construction of phylogenetic trees. Science 155:279–284PubMedCrossRefGoogle Scholar
  63. Flint M, Maidens C, Loomis-Price LD, Shotton C, Dubuisson J, Monk P, Higginbottom A, Levy S, McKeating JA (1999) Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol 73:6235–6244PubMedGoogle Scholar
  64. Flint M, Dubuisson J, Maidens C, Harrop R, Guile GR, Borrow P, McKeating JA (2000) Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein. J Virol 74:702–709PubMedCrossRefGoogle Scholar
  65. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, Bukh J (2000) Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 97:13318–13323PubMedCrossRefGoogle Scholar
  66. Foung S, Perkins S, Kafadar K, Gessner P, Zimmermann U (1990) Development of microfusion techniques to generate human hybridomas. J Immunol Methods 134:35–42PubMedCrossRefGoogle Scholar
  67. Foung SK, Perkins S, Raubitschek A, Larrick J, Lizak G, Fishwild D, Engleman EG, Grumet FC (1984) Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma. J Immunol Methods 70:83–90PubMedCrossRefGoogle Scholar
  68. Franzin F, Efremov DG, Pozzato G, Tulissi P, Batista F, Burrone OR (1995) Clonal B-cell expansions in peripheral blood of HCV-infected patients. Br J Haematol 90:548–552PubMedCrossRefGoogle Scholar
  69. Frasca L, Del Porto P, Tuosto L, Marinari B, Scotta C, Carbonari M, Nicosia A, Piccolella E (1999) Hypervariable region 1 variants act as TCR antagonists for hepatitis C virus-specific CD4+ T cells. J Immunol 163:650–658PubMedGoogle Scholar
  70. Fung SK, Chae HB, Fontana RJ, Conjeevaram H, Marrero J, Oberhelman K, Hussain M, Lok AS (2006) Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol 44:283–290PubMedCrossRefGoogle Scholar
  71. Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M, Rimola A, Rodes J (2002) Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 35:680–687PubMedCrossRefGoogle Scholar
  72. Gastaminza P, Kapadia SB, Chisari FV (2006) Differential biophysical properties of infectious intracellular and secreted hepatitis C virus particles. J Virol 80:11074–11081PubMedCrossRefGoogle Scholar
  73. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, Zarski JP, Drouet E (2002) Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J Med Virol 68:206–215PubMedCrossRefGoogle Scholar
  74. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset FL, Montpellier C, Dubuisson J (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol 79:8400–8409PubMedCrossRefGoogle Scholar
  75. Goyenechea B, Klix N, Yelamos J, Williams GT, Riddell A, Neuberger MS, Milstein C (1997) Cells strongly expressing Ig(kappa) transgenes show clonal recruitment of hypermutation: a role for both MAR and the enhancers. EMBO J 16:3987–3994PubMedCrossRefGoogle Scholar
  76. Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, Murthy KK, Rice CM, Walker CM (2003) HCV persistence and immune evasion in the absence of memory T cell help. Science 302:659–662PubMedCrossRefGoogle Scholar
  77. Gretch DR, Polyak SJ, Wilson JJ, Carithers RL Jr, Perkins JD, Corey L (1996) Tracking hepatitis C virus quasispecies major and minor variants in symptomatic and asymptomatic liver transplant recipients. J Virol 70:7622–7631PubMedGoogle Scholar
  78. Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR, Klenerman P (2001) Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 75:5550–5558PubMedCrossRefGoogle Scholar
  79. Guidotti LG, Chisari FV (2001) Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19:65–91PubMedCrossRefGoogle Scholar
  80. Habersetzer F, Fournillier A, Dubuisson J, Rosa D, Abrignani S, Wychowski C, Nakano I, Trepo C, Desgranges C, Inchauspe G (1998) Characterization of human monoclonal antibodies specific to the hepatitis C virus glycoprotein E2 with in vitro binding neutralization properties. Virology 249:32–41PubMedCrossRefGoogle Scholar
  81. Hadlock KG, Lanford RE, Perkins S, Rowe J, Yang Q, Levy S, Pileri P, Abrignani S, Foung SK (2000) Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J Virol 74:10407–10416PubMedCrossRefGoogle Scholar
  82. Hanley J, Jarvis L, Simmonds P, Parker A, Ludlam C (1996) HCV and non-Hodgkin lymphoma. Lancet 347:1339PubMedCrossRefGoogle Scholar
  83. Harris SL, Craig L, Mehroke JS, Rashed M, Zwick MB, Kenar K, Toone EJ, Greenspan N, Auzanneau FI, Marino-Albernas JR, Pinto BM, Scott JK (1997) Exploring the basis of peptide-carbohydrate crossreactivity: evidence for discrimination by peptides between closely related anti-carbohydrate antibodies. Proc Natl Acad Sci U S A 94:2454–2459PubMedCrossRefGoogle Scholar
  84. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, Purcell RH, Yoshikura H (1993) Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67:1953–1958PubMedGoogle Scholar
  85. Honda M, Kaneko S, Sakai A, Unoura M, Murakami S, Kobayashi K (1994) Degree of diversity of hepatitis C virus quasispecies and progression of liver disease. Hepatology 20:1144–1151PubMedCrossRefGoogle Scholar
  86. Houghton M (1996) The hepatitis C virus. In: Knight DM, Howley PM (eds) Fields virology. Lippincott–Raven, Philadelphia, pp 1035–1058Google Scholar
  87. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM, McKeating JA (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc Natl Acad Sci U S A 100:7271–7276PubMedCrossRefGoogle Scholar
  88. Ishii K, Rosa D, Watanabe Y, Katayama T, Harada H, Wyatt C, Kiyosawa K, Aizaki H, Matsuura Y, Houghton M, Abrignani S, Miyamura T (1998) High titers of antibodies inhibiting the binding of envelope to human cells correlate with natural resolution of chronic hepatitis C. Hepatology 28:1117–1120PubMedCrossRefGoogle Scholar
  89. Ivanovski M, Silvestri F, Pozzato G, Anand S, Mazzaro C, Burrone OR, Efremov DG (1998) Somatic hypermutation, clonal diversity, and preferential expression of the VH 51p1/VL kv325 immunoglobulin gene combination in hepatitis C virus-associated immunocytomas. Blood 91:2433–2442PubMedGoogle Scholar
  90. Kaneko T, Moriyama T, Udaka K, Hiroishi K, Kita H, Okamoto H, Yagita H, Okumura K, Imawari M (1997) Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur J Immunol 27:1782–1787PubMedCrossRefGoogle Scholar
  91. Keck ZY, Op De Beeck A, Hadlock KG, Xia J, Li TK, Dubuisson J, Foung SK (2004a) Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J Virol 78:9224–9232PubMedCrossRefGoogle Scholar
  92. Keck ZY, Sung VM, Perkins S, Rowe J, Paul S, Liang TJ, Lai MM, Foung SK (2004b) Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J Virol 78:7257–7263PubMedCrossRefGoogle Scholar
  93. Keck ZY, Li TK, Xia J, Bartosch B, Cosset FL, Dubuisson J, Foung SK (2005) Analysis of a highly flexible conformational immunogenic domain A in hepatitis C virus E2. J Virol 79:13199–13208PubMedCrossRefGoogle Scholar
  94. Keck ZY, Xia J, Cai Z, Li TK, Owsianka AM, Patel AH, Luo G, Foung SK (2007) Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J Virol 81:1043–1047PubMedCrossRefGoogle Scholar
  95. Kimura Y, Gushima T, Rawale S, Kaumaya P, Walker CM (2005) Escape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection. J Virol 79:4870–4876PubMedCrossRefGoogle Scholar
  96. Kizaki M, Sakashita A, Karmakar A, Lin CW, Koeffler HP (1993) Regulation of manganese superoxide dismutase and other antioxidant genes in normal and leukemic hematopoietic cells and their relationship to cytotoxicity by tumor necrosis factor. Blood 82:1142–1150PubMedGoogle Scholar
  97. Kondo Y, Sung VM, Machida K, Liu M, Lai MM (2007) Hepatitis C virus infects T cells and affects interferon-gamma signaling in T cell lines. Virology 361:161–173PubMedCrossRefGoogle Scholar
  98. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, Houghton M, Walker BD (1995) HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 96:2311–2321PubMedCrossRefGoogle Scholar
  99. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, Kuo G, Spelbring JE, Meeks E, Sinha S, Carson DA (1996) Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173:822–828PubMedGoogle Scholar
  100. Kumar U, Monjardino J, Thomas HC (1994) Hypervariable region of hepatitis C virus envelope glycoprotein (E2/NS1) in an agammaglobulinemic patient. Gastroenterology 106:1072–1075PubMedGoogle Scholar
  101. Lai ME, Mazzoleni AP, Argiolu F, De Virgilis S, Balestrieri A, Purcell RH, Cao A, Farci P (1994) Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic children. Lancet 343:388–390PubMedCrossRefGoogle Scholar
  102. Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL (2005) Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41:265–274PubMedCrossRefGoogle Scholar
  103. Lechner F, Wong DK, Dunbar PR, Chapman R, Chung RT, Dohrenwend P, Robbins G, Phillips R, Klenerman P, Walker BD (2000) Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 191:1499–1512PubMedCrossRefGoogle Scholar
  104. Levy S, Todd SC, Maecker HT (1998) CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 16:89–109PubMedCrossRefGoogle Scholar
  105. Lindenbach BD, Rice CM (2001) Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott–Raven, Philadelphia, pp 991–1041Google Scholar
  106. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM (2005) Complete replication of hepatitis C virus in cell culture. Science 309:623–626PubMedCrossRefGoogle Scholar
  107. Logvinoff C, Major ME, Oldach D, Heyward S, Talal A, Balfe P, Feinstone SM, Alter H, Rice CM, McKeating JA (2004) Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A 101:10149–10154PubMedCrossRefGoogle Scholar
  108. Machida K, Cheng KT, Sung VM, Lee KJ, Levine AM, Lai MM (2004a) Hepatitis C virus infection activates the immunologic (type II) isoform of nitric oxide synthase and thereby enhances DNA damage and mutations of cellular genes. J Virol 78:8835–8843PubMedCrossRefGoogle Scholar
  109. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MM (2004b) Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci U S A 101:4262–4267PubMedCrossRefGoogle Scholar
  110. Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM (2005) Hepatitis C virus E2-CD81 interaction induces hypermutation of the immunoglobulin gene in B cells. J Virol 79:8079–8089PubMedCrossRefGoogle Scholar
  111. Majid A, Jackson P, Lawal Z, Pearson GM, Parker H, Alexander GJ, Allain JP, Petrik J (1999) Ontogeny of hepatitis C virus (HCV) hypervariable region 1 (HVR1) heterogeneity and HVR1 antibody responses over a 3 year period in a patient infected with HCV type 2b. J Gen Virol 80:317–325PubMedGoogle Scholar
  112. Major M, Rehermann B, Feinstone SM (2001) Hepatitis C viruses. In: Knipe DM, Howley PM (eds) Fields virology. Lippincott-Raven, Philadelphia, pp 1127–1162Google Scholar
  113. Martell M, Esteban JI, Quer J, Vargas V, Esteban R, Guardia J, Gomez J (1994) Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation. J Virol 68:3425–3436PubMedGoogle Scholar
  114. McAllister J, Casino C, Davidson F, Power J, Lawlor E, Yap PL, Simmonds P, Smith DB (1998) Long-term evolution of the hypervariable region of hepatitis C virus in a common-source-infected cohort. J Virol 72:4893–4905PubMedGoogle Scholar
  115. McKeating JA, Zhang LQ, Logvinoff C, Flint M, Zhang J, Yu J, Butera D, Ho DD, Dustin LB, Rice CM, Balfe P (2004) Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J Virol 78:8496–8505PubMedCrossRefGoogle Scholar
  116. McLauchlan J, Lemberg MK, Hope G, Martoglio B (2002) Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 21:3980–3988PubMedCrossRefGoogle Scholar
  117. Mehta SH, Cox A, Hoover DR, Wang XH, Mao Q, Ray S, Strathdee SA, Vlahov D, Thomas DL (2002) Protection against persistence of hepatitis C. Lancet 359:1478–1483PubMedCrossRefGoogle Scholar
  118. Meyer K, Basu A, Ray R (2000) Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 276:214–226PubMedCrossRefGoogle Scholar
  119. Meyer K, Basu A, Przysiecki CT, Lagging LM, Di Bisceglie AM, Conley AJ, Ray R (2002) Complement-mediated enhancement of antibody function for neutralization of pseudotype virus containing hepatitis C virus E2 chimeric glycoprotein. J Virol 76:2150–2158PubMedCrossRefGoogle Scholar
  120. Misiani R, Bellavita P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, et al (1994) Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 330:751–756PubMedCrossRefGoogle Scholar
  121. Miyazaki T, Muller U, Campbell KS (1997) Normal development but differentially altered proliferative responses of lymphocytes in mice lacking CD81. EMBO J 16:4217–4225PubMedCrossRefGoogle Scholar
  122. Muramatsu M, Sankaranand VS, Anant S, Sugai M, Kinoshita K, Davidson NO, Honjo T (1999) Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Chem 274:18470–18476PubMedCrossRefGoogle Scholar
  123. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS (1998) Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 282:103–107PubMedCrossRefGoogle Scholar
  124. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL (2006) Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 80:2418–2428PubMedCrossRefGoogle Scholar
  125. Op De Beeck A, Voisset C, Bartosch B, Ciczora Y, Cocquerel L, Keck Z, Foung S, Cosset FL, Dubuisson J (2004) Characterization of functional hepatitis C virus envelope glycoproteins. J Virol 78:2994–3002PubMedCrossRefGoogle Scholar
  126. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH (2001) Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 82:1877–1883PubMedGoogle Scholar
  127. Owsianka A, Tarr AW, Juttla VS, Lavillette D, Bartosch B, Cosset FL, Ball JK, Patel AH (2005) Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol 79:11095–11104PubMedCrossRefGoogle Scholar
  128. Owsianka AM, Timms JM, Tarr AW, Brown RJ, Hickling TP, Szwejk A, Bienkowska-Szewczyk K, Thomson BJ, Patel AH, Ball JK (2006) Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J Virol 80:8695–8704PubMedCrossRefGoogle Scholar
  129. Papavasiliou FN, Schatz DG (2002) Somatic hypermutation of immunoglobulin genes: merging mechanisms for genetic diversity. Cell 109 Suppl:S35–44PubMedCrossRefGoogle Scholar
  130. Penin F, Combet C, Germanidis G, Frainais PO, Deleage G, Pawlotsky JM (2001) Conservation of the conformation and positive charges of hepatitis C virus E2 envelope glycoprotein hypervariable region 1 points to a role in cell attachment. J Virol 75:5703–5710PubMedCrossRefGoogle Scholar
  131. Perkins S, Zimmermann U, Foung SK (1991) Parameters to enhance human hybridoma formation with hypoosmolar electrofusion. Hum Antibodies Hybridomas 2:155–159PubMedGoogle Scholar
  132. Perrillo RP, Wright T, Rakela J, et al (2001) A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis B. Hepatology 33:424–432PubMedCrossRefGoogle Scholar
  133. Pestka JM, Zeisel MB, Bl ser E, Schürmann P, Bartosch B, Cosset F-L, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF (2007) Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci U S A 104:6025–6030PubMedCrossRefGoogle Scholar
  134. Petersen-Mahrt SK, Harris RS, Neuberger MS (2002) AID mutates E. coli suggesting a DNA deamination mechanism for antibody diversification. Nature 418:99–103PubMedCrossRefGoogle Scholar
  135. Piazza M, Sagliocca L, Tosone G, Guadagnino V, Stazi MA, Orlando R, Borgia G, Rosa D, Abrignani S, Palumbo F, Manzin A, Clementi M (1997) Sexual transmission of the hepatitis C virus and efficacy of prophylaxis with intramuscular immune serum globulin. A randomized controlled trial. Arch Intern Med 157:1537–1544PubMedCrossRefGoogle Scholar
  136. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, Abid K, Negro F, Dreux M, Cosset FL, Bartenschlager R (2006) Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 103:7408–7413PubMedCrossRefGoogle Scholar
  137. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G, Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938–941PubMedCrossRefGoogle Scholar
  138. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC (2004) The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon Infection. J Virol 78:5205–5215PubMedCrossRefGoogle Scholar
  139. Post JJ, Pan Y, Freeman AJ, et al (2004) Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 189:1846–1855PubMedCrossRefGoogle Scholar
  140. Pugach P, Kuhmann SE, Taylor J, Marozsan AJ, Snyder A, Ketas T, Wolinsky SM, Korber BT, Moore JP (2004) The prolonged culture of human immunodeficiency virus type 1 in primary lymphocytes increases its sensitivity to neutralization by soluble CD4. Virology 321:8–22PubMedCrossRefGoogle Scholar
  141. Puig M, Major ME, Mihalik K, Feinstone SM (2004) Immunization of chimpanzees with an envelope protein-based vaccine enhances specific humoral and cellular immune responses that delay hepatitis C virus infection. Vaccine 22:991–1000PubMedCrossRefGoogle Scholar
  142. Puntoriero G, Meola A, Lahm A, Zucchelli S, Ercole BB, Tafi R, Pezzanera M, Mondelli MU, Cortese R, Tramontano A, Galfre' G, Nicosia A (1998) Towards a solution for hepatitis C virus hypervariability: mimotopes of the hypervariable region 1 can induce antibodies cross-reacting with a large number of viral variants. EMBO J 17:3521–3533PubMedCrossRefGoogle Scholar
  143. Rada C, Milstein C (2001) The intrinsic hypermutability of antibody heavy and light chain genes decays exponentially. EMBO J 20:4570–4576PubMedCrossRefGoogle Scholar
  144. Radkowski M, Bednarska A, Horban A, Stanczak J, Wilkinson J, Adair DM, Nowicki M, Rakela J, Laskus T (2004) Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-alpha and interleukin 8. J Gen Virol 85:47–59PubMedCrossRefGoogle Scholar
  145. Ray SC, Wang YM, Laeyendecker O, Ticehurst JR, Villano SA, Thomas DL (1999) Acute hepatitis C virus structural gene sequences as predictors of persistent viremia: hypervariable region 1 as a decoy. J Virol 73:2938–2946PubMedGoogle Scholar
  146. Ray SC, Fanning L, Wang XH, Netski DM, Kenny-Walsh E, Thomas DL (2005) Divergent and convergent evolution after a common-source outbreak of hepatitis C virus. J Exp Med 201:1753–1759PubMedCrossRefGoogle Scholar
  147. Robertson B, Myers G, Howard C, et al (1998) Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization. International Committee on Virus Taxonomy. Arch Virol 143:2493–2503PubMedCrossRefGoogle Scholar
  148. Roccasecca R, Folgori A, Ercole BB, Puntoriero G, Lahm A, Zucchelli S, Tafi R, Pezzanera M, Galfre G, Tramontano A, Mondelli MU, Pessi A, Nicosia A, Cortese R, Meola A (2001) Mimotopes of the hyper variable region 1 of the hepatitis C virus induce cross-reactive antibodies directed against discontinuous epitopes. Mol Immunol 38:485–492PubMedCrossRefGoogle Scholar
  149. Rollier C, Depla E, Drexhage JA, Verschoor EJ, Verstrepen BE, Fatmi A, Brinster C, Fournillier A, Whelan JA, Whelan M, Jacobs D, Maertens G, Inchauspe G, Heeney JL (2004) Control of heterologous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine-induced peripheral T-helper immune response. J Virol 78:187–196PubMedCrossRefGoogle Scholar
  150. Rosa D, Campagnoli S, Moretto C, Guenzi E, Cousens L, Chin M, Dong C, Weiner AJ, Lau JY, Choo QL, Chien D, Pileri P, Houghton M, Abrignani S (1996) A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells. Proc Natl Acad Sci U S A 93:1759–1763PubMedCrossRefGoogle Scholar
  151. Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, Alexander GJ (2005) Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection. J Virol 79:7852–7859PubMedCrossRefGoogle Scholar
  152. Sanchez-Quijano A, Pineda JA, Lissen E, Leal M, Diaz-Torres MA, Garcia De Pesquera F, Rivera F, Castro R, Munoz J (1988) Prevention of post-transfusion non-A, non-B hepatitis by non-specific immunoglobulin in heart surgery patients. Lancet 1:1245–1249PubMedCrossRefGoogle Scholar
  153. Sasso EH (2000) The rheumatoid factor response in the etiology of mixed cryoglobulins associated with hepatitis C virus infection. Ann Med Interne (Paris) 151:30–40Google Scholar
  154. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 21:5017–5025PubMedCrossRefGoogle Scholar
  155. Schofield DJ, Bartosch B, Shimizu YK, Allander T, Alter HJ, Emerson SU, Cosset FL, Purcell RH (2005) Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity. Hepatology 42:1055–1062PubMedCrossRefGoogle Scholar
  156. Schreibman IR, Schiff ER (2006) Prevention and treatment of recurrent hepatitis B after liver transplantation: the current role of nucleoside and nucleotide analogues. Ann Clin Microbiol Antimicrob 5:8PubMedCrossRefGoogle Scholar
  157. Seifert U, Liermann H, Racanelli V, Halenius A, Wiese M, Wedemeyer H, Ruppert T, Rispeter K, Henklein P, Sijts A, Hengel H, Kloetzel PM, Rehermann B (2004) Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest 114:250–259PubMedGoogle Scholar
  158. Sheridan I, Pybus OG, Holmes EC, Klenerman P (2004) High-resolution phylogenetic analysis of hepatitis C virus adaptation and its relationship to disease progression. J Virol 78:3447–3454PubMedCrossRefGoogle Scholar
  159. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H (1994) Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 68:1494–1500PubMedGoogle Scholar
  160. Shimizu YK, Igarashi H, Kiyohara T, Cabezon T, Farci P, Purcell RH, Yoshikura H (1996) A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409–412PubMedCrossRefGoogle Scholar
  161. Shoukry NH, Cawthon AG, Walker CM (2004) Cell-mediated immunity and the outcome of hepatitis C virus infection. Annu Rev Microbiol 58:391–424PubMedCrossRefGoogle Scholar
  162. Siemoneit K, Cardoso Mda S, Koerner K, Wolpl A, Kubanek B (1995) Human monoclonal antibodies for the immunological characterization of a highly conserved protein domain of the hepatitis C virus glycoprotein E1. Clin Exp Immunol 101:278–283PubMedGoogle Scholar
  163. Silvestri F, Barillari G, Fanin R, Pipan C, Falasca E, Salmaso F, Zaja F, Infanti L, Patriarca F, Botta GA, Baccarani M (1997) The genotype of the hepatitis C virus in patients with HCV-related B cell non-Hodgkin's lymphoma. Leukemia 11:2157–2161PubMedCrossRefGoogle Scholar
  164. Simmonds P, Bukh J, Combet C, et al (2005) Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42:962–973PubMedCrossRefGoogle Scholar
  165. Smith DB (1999) Evolution of the hypervariable region of hepatitis C virus. J Viral Hepat 6 [Suppl 1]:41–46PubMedCrossRefGoogle Scholar
  166. Smith TJ (2001) Antibody interactions with rhinovirus: lessons for mechanisms of neutralization and the role of immunity in viral evolution. Curr Top Microbiol Immunol 260:1–28PubMedGoogle Scholar
  167. Sneath PHA, Sokal RR (1973) Taxonomic structure. In: Numerical taxonomy. Freeman and Company, San Francisco, pp 230–234Google Scholar
  168. Soldaini E, Wack A, D'Oro U, Nuti S, Ulivieri C, Baldari CT, Abrignani S (2003) T cell costimulation by the hepatitis C virus envelope protein E2 binding to CD81 is mediated by Lck. Eur J Immunol 33:455–464PubMedCrossRefGoogle Scholar
  169. Steinmann D, Barth H, Gissler B, Schurmann P, Adah MI, Gerlach JT, Pape GR, Depla E, Jacobs D, Maertens G, Patel AH, Inchauspe G, Liang TJ, Blum HE, Baumert TF (2004) Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J Virol 78:9030–9040PubMedCrossRefGoogle Scholar
  170. Sugg U, Schneider W, Hoffmeister HE, Huth C, Stephan W, Lissner R, Haase W (1985) Hepatitis B immune globulin to prevent non-A, non-B post-transfusion hepatitis. Lancet 1:405–406PubMedCrossRefGoogle Scholar
  171. Sullivan J, Swofford DL, Naylor JP (1999) The effect of taxon sampling on estimating rate heterogeneity parameters of maximum-likelihood models. Mol Biol Evol 16:1347–1356Google Scholar
  172. Sung VM, Shimodaira S, Doughty AL, Picchio GR, Can H, Yen TS, Lindsay KL, Levine AM, Lai MM (2003) Establishment of B-cell lymphoma cell lines persistently infected with hepatitis C virus in vivo and in vitro: the apoptotic effects of virus infection. J Virol 77:2134–2146PubMedCrossRefGoogle Scholar
  173. Takahashi S, Doss C, Levy S, Levy R (1990) TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol 145:2207–2213PubMedGoogle Scholar
  174. Tarr AW, Owsianka AM, Timms JM, McClure CP, Brown RJ, Hickling TP, Pietschmann T, Bartenschlager R, Patel AH, Ball JK (2006) Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology 43:592–601PubMedCrossRefGoogle Scholar
  175. Tester I, Smyk-Pearson S, Wang P, Wertheimer A, Yao E, Lewinsohn DM, Tavis JE, Rosen HR (2005) Immune evasion versus recovery after acute hepatitis C virus infection from a shared source. J Exp Med 201:1725–1731PubMedCrossRefGoogle Scholar
  176. Timm J, Lauer GM, Kavanagh DG, Sheridan I, Kim AY, Lucas M, Pillay T, Ouchi K, Reyor LL, Schulze zur Wiesch J, Gandhi RT, Chung RT, Bhardwaj N, Klenerman P, Walker BD, Allen TM (2004) CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200:1593–1604PubMedCrossRefGoogle Scholar
  177. Triyatni M, Vergalla J, Davis AR, Hadlock KG, Foung SK, Liang TJ (2002) Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298:124–132PubMedCrossRefGoogle Scholar
  178. Tsai SL, Chen YM, Chen MH, Huang CY, Sheen IS, Yeh CT, Huang JH, Kuo GC, Liaw YF (1998) Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology 115:954–965PubMedCrossRefGoogle Scholar
  179. Tseng CT, Klimpel GR (2002) Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J Exp Med 195:43–49PubMedCrossRefGoogle Scholar
  180. Voisset C, Op de Beeck A, Horellou P, Dreux M, Gustot T, Duverlie G, Cosset FL, Vu-Dac N, Dubuisson J (2006) High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry. J Gen Virol 87:2577–2581PubMedCrossRefGoogle Scholar
  181. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA (2007) Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 132:667–678CrossRefGoogle Scholar
  182. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R, Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 11:791–796PubMedCrossRefGoogle Scholar
  183. Wedemeyer H, He XS, Nascimbeni M, Davis AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H, Rehermann B (2002) Impaired effector function of hepatitis C virus-specific CD8+ T cells in chronic hepatitis C virus infection. J Immunol 169:3447–3458PubMedGoogle Scholar
  184. Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, Houghton M, Walker CM (1995) Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 92:2755–2759PubMedCrossRefGoogle Scholar
  185. Weng WK, Levy S (2003) Hepatitis C virus (HCV) and lymphomagenesis. Leuk Lymphoma 44:1113–1120PubMedCrossRefGoogle Scholar
  186. Wong GH, Goeddel DV (1988) Induction of manganous superoxide dismutase by tumor necrosis factor: possible protective mechanism. Science 242:941–944PubMedCrossRefGoogle Scholar
  187. Yang Z, Bielawski JP (2000) Statistical methods for detecting molecular adaptation. Trends Ecol Evol 15:496–503PubMedCrossRefGoogle Scholar
  188. Yi M, Villanueva RA, Thomas DL, Wakita T, Lemon SM (2006) Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc Natl Acad Sci U S A 103:2310–2315PubMedCrossRefGoogle Scholar
  189. Zan H, Komori A, Li Z, Cerutti A, Schaffer A, Flajnik MF, Diaz M, Casali P (2001) The translesion DNA polymerase zeta plays a major role in Ig and bcl-6 somatic hypermutation. Immunity 14:643–653PubMedCrossRefGoogle Scholar
  190. Zeng X, Winter DB, Kasmer C, Kraemer KH, Lehmann AR, Gearhart PJ (2001) DNA polymerase eta is an A-T mutator in somatic hypermutation of immunoglobulin variable genes. Nat Immunol 2:537–541PubMedCrossRefGoogle Scholar
  191. Zhang J, Randall G, Higginbottom A, Monk P, Rice CM, McKeating JA (2004) CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J Virol 78:1448–1455PubMedCrossRefGoogle Scholar
  192. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T, Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 102:9294–9299PubMedCrossRefGoogle Scholar
  193. Zhou YH, Shimizu YK, Esumi M (2000) Monoclonal antibodies to the hypervariable region 1 of hepatitis C virus capture virus and inhibit virus adsorption to susceptible cells in vitro. Virology 269:276–283PubMedCrossRefGoogle Scholar
  194. Zibert A, Schreier E, Roggendorf M (1995) Antibodies in human sera specific to hypervariable region 1 of hepatitis C virus can block viral attachment. Virology 208:653–661PubMedCrossRefGoogle Scholar
  195. Zibert A, Kraas W, Meisel H, Jung G, Roggendorf M (1997) Epitope mapping of antibodies directed against hypervariable region 1 in acute self-limiting and chronic infections due to hepatitis C virus. J Virol 71:4123–4127PubMedGoogle Scholar
  196. Zimmermann U, Gessner P, Schnettler R, Perkins S, Foung SK (1990) Efficient hybridization of mouse-human cell lines by means of hypo-osmolar electrofusion. J Immunol Methods 134:43–50PubMedCrossRefGoogle Scholar
  197. Zucchelli S, Roccasecca R, Meola A, Ercole BB, Tafi R, Dubuisson J, Galfre G, Cortese R, Nicosia A (2001) Mimotopes of the hepatitis C virus hypervariable region 1, but not the natural sequences, induce cross-reactive antibody response by genetic immunization. Hepatology 33:692–703PubMedCrossRefGoogle Scholar
  198. Zuckerman E, Zuckerman T, Levine AM, Douer D, Gutekunst K, Mizokami M, Qian DG, Velankar M, Nathwani BN, Fong TL (1997) Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma. Ann Intern Med 127:423–428PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2008

Authors and Affiliations

  • K. Machida
    • 1
  • Z. Y. Keck
    • 2
  • M. M. C. Lai
    • 1
  • J. K. Ball
    • 3
  • A. H. Patel
    • 4
  • S. K. H. Foung
    • 2
  1. 1.Department of Molecular Microbiology and ImmunologyUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Department of PathologyStanford Medical School Blood CenterPalo AltoUSA
  3. 3.Institute of Infection, Immunity and InflammationThe University of Nottingham, Queen's Medical CentreUK
  4. 4.MRC Virology Unit, Institute of VirologyUniversity of GlasgowUK

Personalised recommendations